Based on clinical data of NF1-associated glioma, the MTB recommended treatment with the MEK-inhibitor (MEKi) Selumetinib (ESCAT IIIA).25,26 Treatment with selumetinib was initiated after further clinical deterioration and progression on an MRI scan performed after 2 cycles of CCNU. Here, MAP2K7 is linked to central nervous system cancer.